2017 Q3 Form 10-Q Financial Statement
#000114420417052741 Filed on October 17, 2017
Income Statement
| Concept | 2017 Q3 | 2016 Q3 | 2016 Q2 |
|---|---|---|---|
| Revenue | $0.00 | $0.00 | $0.00 |
| YoY Change | |||
| Cost Of Revenue | |||
| YoY Change | |||
| Gross Profit | |||
| YoY Change | |||
| Gross Profit Margin | |||
| Selling, General & Admin | $1.220M | $850.0K | $830.0K |
| YoY Change | 43.53% | -20.56% | -16.16% |
| % of Gross Profit | |||
| Research & Development | $1.168M | $790.0K | $151.0K |
| YoY Change | 47.85% | -47.33% | -89.02% |
| % of Gross Profit | |||
| Depreciation & Amortization | $23.00K | $17.00K | $22.00K |
| YoY Change | 35.29% | -15.0% | -26.67% |
| % of Gross Profit | |||
| Operating Expenses | $1.168M | $1.640M | $151.0K |
| YoY Change | -28.78% | -36.19% | -89.02% |
| Operating Profit | -$2.392M | -$983.0K | |
| YoY Change | -58.4% | ||
| Interest Expense | |||
| YoY Change | |||
| % of Operating Profit | |||
| Other Income/Expense, Net | -$10.00K | $30.00K | $20.00K |
| YoY Change | -133.33% | -200.0% | -80.0% |
| Pretax Income | -$2.400M | -$1.610M | -$960.0K |
| YoY Change | 49.07% | -38.08% | -57.71% |
| Income Tax | |||
| % Of Pretax Income | |||
| Net Earnings | -$2.403M | -$1.606M | -$962.0K |
| YoY Change | 49.63% | -38.3% | -57.53% |
| Net Earnings / Revenue | |||
| Basic Earnings Per Share | |||
| Diluted Earnings Per Share | -$128.1K | -$86.28K | -$51.47K |
| COMMON SHARES | |||
| Basic Shares Outstanding | 18.65M shares | ||
| Diluted Shares Outstanding |
Balance Sheet
| Concept | 2017 Q3 | 2016 Q3 | 2016 Q2 |
|---|---|---|---|
| SHORT-TERM ASSETS | |||
| Cash & Short-Term Investments | $10.55M | $11.19M | $11.48M |
| YoY Change | -5.72% | -34.75% | -41.73% |
| Cash & Equivalents | $2.464M | $955.0K | $944.0K |
| Short-Term Investments | $8.080M | $10.24M | $10.54M |
| Other Short-Term Assets | $90.00K | $80.00K | $70.00K |
| YoY Change | 12.5% | -33.33% | -36.36% |
| Inventory | |||
| Prepaid Expenses | |||
| Receivables | $320.0K | $110.0K | $1.270M |
| Other Receivables | $0.00 | $0.00 | $0.00 |
| Total Short-Term Assets | $10.95M | $11.39M | $12.81M |
| YoY Change | -3.86% | -37.04% | -36.14% |
| LONG-TERM ASSETS | |||
| Property, Plant & Equipment | $360.0K | $310.0K | $318.0K |
| YoY Change | 16.13% | 15.67% | 12.77% |
| Goodwill | |||
| YoY Change | |||
| Intangibles | |||
| YoY Change | |||
| Long-Term Investments | |||
| YoY Change | |||
| Other Assets | $30.00K | $30.00K | $341.0K |
| YoY Change | 0.0% | 1605.0% | |
| Total Long-Term Assets | $390.0K | $330.0K | $344.0K |
| YoY Change | 18.18% | 23.13% | 13.53% |
| TOTAL ASSETS | |||
| Total Short-Term Assets | $10.95M | $11.39M | $12.81M |
| Total Long-Term Assets | $390.0K | $330.0K | $344.0K |
| Total Assets | $11.34M | $11.72M | $13.15M |
| YoY Change | -3.24% | -36.16% | -35.4% |
| SHORT-TERM LIABILITIES | |||
| YoY Change | |||
| Accounts Payable | $280.0K | $350.0K | $355.0K |
| YoY Change | -20.0% | 4.48% | -52.98% |
| Accrued Expenses | $200.0K | $580.0K | $652.0K |
| YoY Change | -65.52% | -74.87% | -56.68% |
| Deferred Revenue | |||
| YoY Change | |||
| Short-Term Debt | $0.00 | $0.00 | $0.00 |
| YoY Change | |||
| Long-Term Debt Due | $0.00 | $0.00 | |
| YoY Change | |||
| Total Short-Term Liabilities | $6.140M | $1.200M | $1.282M |
| YoY Change | 411.67% | -57.72% | -49.25% |
| LONG-TERM LIABILITIES | |||
| Long-Term Debt | $0.00 | $0.00 | $0.00 |
| YoY Change | |||
| Other Long-Term Liabilities | |||
| YoY Change | |||
| Total Long-Term Liabilities | $0.00 | $0.00 | $0.00 |
| YoY Change | |||
| TOTAL LIABILITIES | |||
| Total Short-Term Liabilities | $6.140M | $1.200M | $1.282M |
| Total Long-Term Liabilities | $0.00 | $0.00 | $0.00 |
| Total Liabilities | $6.140M | $1.200M | $1.280M |
| YoY Change | 411.67% | -57.72% | -49.33% |
| SHAREHOLDERS EQUITY | |||
| Retained Earnings | -$72.89M | ||
| YoY Change | 10.19% | ||
| Common Stock | $84.75M | ||
| YoY Change | |||
| Preferred Stock | |||
| YoY Change | |||
| Treasury Stock (at cost) | |||
| YoY Change | |||
| Treasury Stock Shares | |||
| Shareholders Equity | $5.200M | $10.53M | $11.87M |
| YoY Change | |||
| Total Liabilities & Shareholders Equity | $11.34M | $11.72M | $13.15M |
| YoY Change | -3.24% | -36.16% | -35.39% |
Cashflow Statement
| Concept | 2017 Q3 | 2016 Q3 | 2016 Q2 |
|---|---|---|---|
| OPERATING ACTIVITIES | |||
| Net Income | -$2.403M | -$1.606M | -$962.0K |
| YoY Change | 49.63% | -38.3% | -57.53% |
| Depreciation, Depletion And Amortization | $23.00K | $17.00K | $22.00K |
| YoY Change | 35.29% | -15.0% | -26.67% |
| Cash From Operating Activities | $3.843M | -$270.0K | -$1.410M |
| YoY Change | -1523.33% | -89.33% | -14.55% |
| INVESTING ACTIVITIES | |||
| Capital Expenditures | $86.00K | $11.00K | $59.00K |
| YoY Change | 681.82% | -8.33% | -468.75% |
| Acquisitions | |||
| YoY Change | |||
| Other Investing Activities | -$7.150M | $300.0K | $200.0K |
| YoY Change | -2483.33% | -84.62% | -137.74% |
| Cash From Investing Activities | -$7.238M | $290.0K | $130.0K |
| YoY Change | -2595.86% | -85.05% | -123.64% |
| FINANCING ACTIVITIES | |||
| Cash Dividend Paid | |||
| YoY Change | |||
| Common Stock Issuance & Retirement, Net | |||
| YoY Change | |||
| Debt Paid & Issued, Net | |||
| YoY Change | |||
| Cash From Financing Activities | $75.00K | 0.000 | 0.000 |
| YoY Change | -100.0% | ||
| NET CHANGE | |||
| Cash From Operating Activities | $3.843M | -270.0K | -1.410M |
| Cash From Investing Activities | -$7.238M | 290.0K | 130.0K |
| Cash From Financing Activities | $75.00K | 0.000 | 0.000 |
| Net Change In Cash | -$3.320M | 20.00K | -1.280M |
| YoY Change | -16700.0% | -103.39% | -41.55% |
| FREE CASH FLOW | |||
| Cash From Operating Activities | $3.843M | -$270.0K | -$1.410M |
| Capital Expenditures | $86.00K | $11.00K | $59.00K |
| Free Cash Flow | $3.757M | -$281.0K | -$1.469M |
| YoY Change | -1437.01% | -88.95% | -10.1% |
Facts In Submission
| Frame | Concept Type | Concept / XBRL Key | Value | Unit |
|---|---|---|---|---|
| CY2017Q3 | us-gaap |
Stock Option Plan Expense
StockOptionPlanExpense
|
215000 | USD |
| CY2017Q3 | us-gaap |
Increase Decrease In Other Accounts Payable And Accrued Liabilities
IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities
|
131000 | USD |
| CY2016Q3 | us-gaap |
Increase Decrease In Other Accounts Payable And Accrued Liabilities
IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities
|
-84000 | USD |
| CY2017Q3 | us-gaap |
Net Cash Provided By Used In Operating Activities Continuing Operations
NetCashProvidedByUsedInOperatingActivitiesContinuingOperations
|
3843000 | USD |
| CY2016Q3 | us-gaap |
Net Cash Provided By Used In Operating Activities Continuing Operations
NetCashProvidedByUsedInOperatingActivitiesContinuingOperations
|
-275000 | USD |
| CY2016Q3 | bcli |
Financial Expenses Income Net
FinancialExpensesIncomeNet
|
-32000 | USD |
| CY2017Q3 | us-gaap |
Net Income Loss
NetIncomeLoss
|
-2403000 | USD |
| CY2016Q3 | us-gaap |
Net Income Loss
NetIncomeLoss
|
-1606000 | USD |
| CY2017Q3 | us-gaap |
Income Loss From Continuing Operations Per Basic And Diluted Share
IncomeLossFromContinuingOperationsPerBasicAndDilutedShare
|
-0.13 | |
| CY2016Q3 | us-gaap |
Income Loss From Continuing Operations Per Basic And Diluted Share
IncomeLossFromContinuingOperationsPerBasicAndDilutedShare
|
-0.09 | |
| CY2017Q3 | us-gaap |
Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
|
18783997 | shares |
| CY2016Q3 | us-gaap |
Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
|
18656615 | shares |
| CY2015Q4 | us-gaap |
Stockholders Equity
StockholdersEquity
|
14128000 | USD |
| CY2016 | us-gaap |
Stock Granted During Period Value Sharebased Compensation
StockGrantedDuringPeriodValueSharebasedCompensation
|
121000 | USD |
| CY2016 | us-gaap |
Stock Issued During Period Value Share Based Compensation
StockIssuedDuringPeriodValueShareBasedCompensation
|
635000 | USD |
| CY2016 | us-gaap |
Net Income Loss
NetIncomeLoss
|
-4982000 | USD |
| us-gaap |
Depreciation
Depreciation
|
57000 | USD | |
| us-gaap |
Depreciation
Depreciation
|
55000 | USD | |
| us-gaap |
Net Cash Provided By Used In Operating Activities Continuing Operations
NetCashProvidedByUsedInOperatingActivitiesContinuingOperations
|
571000 | USD | |
| us-gaap |
Net Cash Provided By Used In Operating Activities Continuing Operations
NetCashProvidedByUsedInOperatingActivitiesContinuingOperations
|
-4662000 | USD | |
| us-gaap |
Stock Option Plan Expense
StockOptionPlanExpense
|
398000 | USD | |
| us-gaap |
Stock Option Plan Expense
StockOptionPlanExpense
|
636000 | USD | |
| us-gaap |
Issuance Of Stock And Warrants For Services Or Claims
IssuanceOfStockAndWarrantsForServicesOrClaims
|
18000 | USD | |
| bcli |
Increase Decrease In Accounts Receivable And Prepaid Expenses
IncreaseDecreaseInAccountsReceivableAndPrepaidExpenses
|
-50000 | USD | |
| us-gaap |
Increase Decrease In Other Accounts Payable And Accrued Liabilities
IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities
|
96000 | USD | |
| us-gaap |
Increase Decrease In Other Accounts Payable And Accrued Liabilities
IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities
|
-940000 | USD | |
| CY2017Q3 | us-gaap |
Depreciation
Depreciation
|
23000 | USD |
| CY2016Q3 | us-gaap |
Depreciation
Depreciation
|
17000 | USD |
| CY2017Q3 | us-gaap |
Issuance Of Stock And Warrants For Services Or Claims
IssuanceOfStockAndWarrantsForServicesOrClaims
|
18000 | USD |
| CY2016Q3 | us-gaap |
Issuance Of Stock And Warrants For Services Or Claims
IssuanceOfStockAndWarrantsForServicesOrClaims
|
90000 | USD |
| CY2016Q3 | us-gaap |
Stock Option Plan Expense
StockOptionPlanExpense
|
171000 | USD |
| CY2017Q3 | bcli |
Increase Decrease In Accounts Receivable And Prepaid Expenses
IncreaseDecreaseInAccountsReceivableAndPrepaidExpenses
|
-561000 | USD |
| CY2016Q3 | bcli |
Increase Decrease In Accounts Receivable And Prepaid Expenses
IncreaseDecreaseInAccountsReceivableAndPrepaidExpenses
|
-1140000 | USD |
| us-gaap |
Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
|
118000 | USD | |
| us-gaap |
Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
|
96000 | USD | |
| us-gaap |
Payments For Proceeds From Investments
PaymentsForProceedsFromInvestments
|
-1360000 | USD | |
| us-gaap |
Payments For Proceeds From Investments
PaymentsForProceedsFromInvestments
|
-5289000 | USD | |
| bcli |
Investment In Lease Deposit
InvestmentInLeaseDeposit
|
1000 | USD | |
| bcli |
Investment In Lease Deposit
InvestmentInLeaseDeposit
|
4000 | USD | |
| us-gaap |
Net Cash Provided By Used In Investing Activities Continuing Operations
NetCashProvidedByUsedInInvestingActivitiesContinuingOperations
|
1241000 | USD | |
| us-gaap |
Net Cash Provided By Used In Investing Activities Continuing Operations
NetCashProvidedByUsedInInvestingActivitiesContinuingOperations
|
5189000 | USD | |
| us-gaap |
Net Cash Provided By Used In Financing Activities Continuing Operations
NetCashProvidedByUsedInFinancingActivitiesContinuingOperations
|
105000 | USD | |
| us-gaap |
Net Cash Provided By Used In Financing Activities Continuing Operations
NetCashProvidedByUsedInFinancingActivitiesContinuingOperations
|
0 | USD | |
| us-gaap |
Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
|
1917000 | USD | |
| us-gaap |
Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
|
527000 | USD | |
| CY2015Q4 | us-gaap |
Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
|
428000 | USD |
| CY2016Q3 | us-gaap |
Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
|
955000 | USD |
| CY2017Q3 | us-gaap |
Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
|
86000 | USD |
| CY2016Q3 | us-gaap |
Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
|
11000 | USD |
| CY2017Q3 | us-gaap |
Payments For Proceeds From Investments
PaymentsForProceedsFromInvestments
|
7150000 | USD |
| CY2016Q3 | us-gaap |
Payments For Proceeds From Investments
PaymentsForProceedsFromInvestments
|
-299000 | USD |
| CY2017Q3 | bcli |
Investment In Lease Deposit
InvestmentInLeaseDeposit
|
2000 | USD |
| CY2016Q3 | bcli |
Investment In Lease Deposit
InvestmentInLeaseDeposit
|
2000 | USD |
| CY2017Q3 | us-gaap |
Net Cash Provided By Used In Investing Activities Continuing Operations
NetCashProvidedByUsedInInvestingActivitiesContinuingOperations
|
-7238000 | USD |
| CY2016Q3 | us-gaap |
Net Cash Provided By Used In Investing Activities Continuing Operations
NetCashProvidedByUsedInInvestingActivitiesContinuingOperations
|
286000 | USD |
| CY2017Q3 | us-gaap |
Net Cash Provided By Used In Financing Activities Continuing Operations
NetCashProvidedByUsedInFinancingActivitiesContinuingOperations
|
75000 | USD |
| CY2016Q3 | us-gaap |
Net Cash Provided By Used In Financing Activities Continuing Operations
NetCashProvidedByUsedInFinancingActivitiesContinuingOperations
|
0 | USD |
| CY2017Q3 | us-gaap |
Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
|
-3320000 | USD |
| CY2016Q3 | us-gaap |
Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
|
11000 | USD |
| CY2017Q2 | us-gaap |
Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
|
5784000 | USD |
| CY2016Q2 | us-gaap |
Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
|
944000 | USD |
| us-gaap |
Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
|
105000 | USD | |
| us-gaap |
Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
|
0 | USD | |
| CY2017Q3 | us-gaap |
Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
|
75000 | USD |
| CY2016Q3 | us-gaap |
Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
|
0 | USD |
| CY2014Q4 | us-gaap |
Common Stock Shares Authorized
CommonStockSharesAuthorized
|
800000000 | shares |
| CY2015Q3 | us-gaap |
Common Stock Shares Authorized
CommonStockSharesAuthorized
|
100000000 | shares |
| bcli |
Percentage Of Royalty Paymentif Licensed Product Covered By Valid Claim Or Orphan Drug Status
PercentageOfRoyaltyPaymentifLicensedProductCoveredByValidClaimOrOrphanDrugStatus
|
0.05 | pure | |
| bcli |
Validity Of Royalty Payment Not Covered By Valid Claim Or Orphan Drug Status
ValidityOfRoyaltyPaymentNotCoveredByValidClaimOrOrphanDrugStatus
|
P15Y | ||
| bcli |
Percentage Of Royalty Payment If Licensed Product Not Covered By Valid Claim Or Orphan Drug Status
PercentageOfRoyaltyPaymentIfLicensedProductNotCoveredByValidClaimOrOrphanDrugStatus
|
0.03 | pure | |
| us-gaap |
Maturity Of Time Deposits
MaturityOfTimeDeposits
|
P10M | ||
| CY2016 | us-gaap |
Maturity Of Time Deposits
MaturityOfTimeDeposits
|
P5M | |
| CY2012Q3 | us-gaap |
Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
|
4900000 | USD |
| us-gaap |
Share Based Compensation
ShareBasedCompensation
|
416000 | USD | |
| us-gaap |
Share Based Compensation
ShareBasedCompensation
|
667000 | USD | |
| CY2009Q4 | us-gaap |
Stock Issued During Period Shares Conversion Of Convertible Securities
StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities
|
74667 | shares |
| CY2017Q3 | us-gaap |
Share Based Compensation
ShareBasedCompensation
|
233000 | USD |
| CY2016Q3 | us-gaap |
Share Based Compensation
ShareBasedCompensation
|
171000 | USD |
| CY2016Q4 | bcli |
Deferred Grant Income
DeferredGrantIncome
|
0 | USD |
| CY2017Q3 | bcli |
Deferred Grant Income
DeferredGrantIncome
|
5250000 | USD |
| CY2017Q3 | us-gaap |
Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
|
0.00005 | |
| CY2016Q4 | us-gaap |
Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
|
0.00005 | |
| CY2017Q3 | us-gaap |
Common Stock Shares Authorized
CommonStockSharesAuthorized
|
100000000 | shares |
| CY2016Q4 | us-gaap |
Common Stock Shares Authorized
CommonStockSharesAuthorized
|
100000000 | shares |
| CY2017Q3 | us-gaap |
Common Stock Shares Issued
CommonStockSharesIssued
|
18842726 | shares |
| CY2017Q3 | us-gaap |
Common Stock Shares Outstanding
CommonStockSharesOutstanding
|
18842726 | shares |
| CY2016Q4 | us-gaap |
Common Stock Shares Issued
CommonStockSharesIssued
|
18687987 | shares |
| CY2016Q4 | us-gaap |
Common Stock Shares Outstanding
CommonStockSharesOutstanding
|
18687987 | shares |
| us-gaap |
Stock Granted During Period Value Sharebased Compensation
StockGrantedDuringPeriodValueSharebasedCompensation
|
18000 | USD | |
| bcli |
Stock Issued During Period Value Exercise Of Warrants
StockIssuedDuringPeriodValueExerciseOfWarrants
|
75000 | USD | |
| us-gaap |
Increase Decrease In Accounts Payable Trade
IncreaseDecreaseInAccountsPayableTrade
|
-70000 | USD | |
| bcli |
Increase Decrease In Deferred Grant Income
IncreaseDecreaseInDeferredGrantIncome
|
5250000 | USD | |
| bcli |
Increase Decrease In Deferred Grant Income
IncreaseDecreaseInDeferredGrantIncome
|
0 | USD | |
| CY2017Q3 | bcli |
Increase Decrease In Deferred Grant Income
IncreaseDecreaseInDeferredGrantIncome
|
5250000 | USD |
| CY2016Q3 | bcli |
Increase Decrease In Deferred Grant Income
IncreaseDecreaseInDeferredGrantIncome
|
0 | USD |
| us-gaap |
Use Of Estimates
UseOfEstimates
|
<div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt 85.05pt" align="justify"></div> <table style="clear:both;WIDTH: 100%; FONT-SIZE: 10pt" border="0" cellspacing="0" cellpadding="0" width="100%"> <tr> <td style="BORDER-BOTTOM: #d4d0c8; BORDER-LEFT: #d4d0c8; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; WIDTH: 56.7pt; PADDING-RIGHT: 0in; BORDER-TOP: #d4d0c8; BORDER-RIGHT: #d4d0c8; PADDING-TOP: 0in" valign="top" width="76"> <div style="CLEAR:both;CLEAR: both"><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> </font></div> </td> <td style="BORDER-BOTTOM: #d4d0c8; BORDER-LEFT: #d4d0c8; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; WIDTH: 28.35pt; PADDING-RIGHT: 0in; BORDER-TOP: #d4d0c8; BORDER-RIGHT: #d4d0c8; PADDING-TOP: 0in" valign="top" width="38"> <div style="CLEAR:both;MARGIN: 0in 0in 0pt"><b><font style="FONT-SIZE: 10pt"><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> </font>D.</font></b></div> </td> <td style="BORDER-BOTTOM: #d4d0c8; BORDER-LEFT: #d4d0c8; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; PADDING-RIGHT: 0in; BORDER-TOP: #d4d0c8; BORDER-RIGHT: #d4d0c8; PADDING-TOP: 0in" valign="top"> <div style="CLEAR:both;MARGIN: 0in 0in 0pt" align="justify"><b> <font style="FONT-SIZE: 10pt">Use of estimates</font></b></div> </td> </tr> </table> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: -28.35pt; MARGIN: 0in 0in 0pt 85.05pt" align="justify"><b><font style="FONT-SIZE: 10pt">  </font></b></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt 85.05pt" align="justify"><font style="FONT-SIZE: 10pt">The preparation of financial statements in conformity with generally accepted accounting principles requires management to make estimates and assumptions that affect the amounts reported in the financial statements and accompanying notes. Actual results could differ from those estimates.</font></div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table> | ||
| us-gaap |
Stockholders Equity Reverse Stock Split
StockholdersEquityReverseStockSplit
|
1-for-15 | ||
| us-gaap |
Proceeds From Issuance Or Sale Of Equity
ProceedsFromIssuanceOrSaleOfEquity
|
46600000 | USD |
